Clinical Trial Update: RO4929097 in Treating Patients With Recurrent Invasive Gliomas [Phase 1]

View source ↗

Summary

Phase 1 trial update for RO4929097 in recurrent invasive gliomas has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Oligodendroglioma
• Brainstem Glioma
• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma
• Oligoastrocytoma

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma | Phase 1 | Status: TERMINATED